MPLT
NASDAQ · Biotechnology
Maplight Therapeutics Inc
$17.80
+0.82 (+4.83%)
Financial Highlights (FY 2025)
Revenue
110.57M
Net Income
-5,057,192
Gross Margin
37.2%
Profit Margin
-4.6%
Rev Growth
+23.3%
D/E Ratio
0.30
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 37.2% | 37.2% | 37.2% |
| Operating Margin | -6.1% | -6.3% | -6.5% |
| Profit Margin | -4.6% | -4.4% | -5.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.57M | 109.60M | 110.00M |
| Gross Profit | 41.18M | 40.81M | 40.96M |
| Operating Income | -6,746,326 | -6,891,610 | -7,104,885 |
| Net Income | -5,057,192 | -4,807,023 | -6,303,306 |
| Gross Margin | 37.2% | 37.2% | 37.2% |
| Operating Margin | -6.1% | -6.3% | -6.5% |
| Profit Margin | -4.6% | -4.4% | -5.7% |
| Rev Growth | +23.3% | +7.4% | -2.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 145.33M | 180.43M | 164.61M |
| Total Equity | 489.86M | 475.01M | 472.39M |
| D/E Ratio | 0.30 | 0.38 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -7,551,548 | -8,325,034 | -7,754,101 |
| Free Cash Flow | -7,533,825 | -4,832,804 | -6,604,673 |